Best Life Sciences Companies in Ottawa, Canada
The 41 best Life Sciences companies in Ottawa, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Epocal.
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Ottawa
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Epocal Biochips and Solid state diagnostic devices | $41M | 232 mo ago | Acqui-Hired | — | 2001 | — | 53 patents Point‑of‑care fluidic diagnostic devices and heterogeneous membrane electrode technologies | — |
| 2 | Tetra Bio-Pharma Developer of natural medicinal plant-based elements for treating multiple diseases 32Funding top 26%Talent bottom 49%Market bottom 41%Tech bottom 38% All 6 signals ▾Fundingtop 26% Talentbottom 49% Marketbottom 41% Techbottom 38% Globalbottom 36% Newsbottom 24% Funding: Raised $37.9M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 32/100 | $38M | 42 mo ago | Public | Andre Audet Co-Founder | 2015 | — | — | — |
| 3 | DistillerSR AI enabled literature review automation software for life sciences researchers | $21M | 48 mo ago | Series A | Peter Blenis Co-Founder & CEO | 2008 | WordPressApple iCloud MailGoogle Workspace+29 | 2 patents Automated extraction of structured data from unstructured documents and articles | — |
| 4 | Spiderwort Developer of plant-based biomaterials for repair and regeneration of tissues | $16M | 49 mo ago | Series A | — | 2017 | — | 60 patents Plant-derived biopolymer scaffolds, microfluidic channels, and dermal fillers for tissue engineering | — |
| 5 | Virica Biotech Developer of viral sensitizer technology therapeutics to treat viral infections | $12M | 28 mo ago | Series A | Jean Diallo Founder & CEO | 2018 | WordPressMySQLPHP+31 | 4 patents Enhancing viral vector yields using kinase inhibitor‑based production methods | 1 launch |
| 6 | CryoStasis Developer of subzero unfrozen cell preservation platform for cell and gene therapy | $8M | 37 mo ago | Seed | — | 2022 | — | 10 patents Cryogenic preservation and storage systems for biological specimens | — |
| 7 | Atreus Pharmaceuticals Developing in vivo imaging diagnostic candidates for autoimmune diseases | $6M | 198 mo ago | Acqui-Hired | Bill Dickie CEO | 2007 | — | — | — |
| 8 | Esphera SynBio Developer of cancer and immunoregulatory treatments using synthetic biology 45Talent top 28%Funding top 45%Global bottom 33% All 3 signals ▾Talenttop 28% Fundingtop 45% Globalbottom 33% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.4M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $2M | 3 mo ago | Seed | John Bell Co-Founder | 2022 | — | — | — |
| 9 | GaitTronics Develops robots for effortless mobility for seniors | $600K | 170 mo ago | Early Stage | — | 2012 | — | 5 patents Assistive gait control systems for patient rehabilitation and mobility support | — |
| 10 | iBIONICS Implantable bionic devices that will help return autonomy and partial vision to the blind | $438K | 97 mo ago | Funding Raised | — | 2015 | — | 8 patents Wireless optical power and data transmission via collimated beams | — |
| 11 | Spartan Bioscience DNA testing systems | $284K | 137 mo ago | Series A | — | 2005 | — | 57 patents Point-of-care nucleic acid extraction and amplification devices for rapid diagnostic testing | — |
| 12 | NeuroQore Develops a monophasic repetitive transcranial magnetic stimulation (rTMS) system | $250K | 13 mo ago | Series A | — | 2012 | — | — | — |
Top 12 Life Sciences companies in Ottawa
#1
Seed · Ottawa, Ontario · founded 2022$2.4Mraised▾
Developer of cancer and immunoregulatory treatments using synthetic biology. The platform focuses on altering tumor-derived exosomes in vivo such that they become immunostimulatory, antigen-bearing TME and patient-specific cancer vaccines.
- May 2026Seed$365.5K
- Jan 2025Seed$2M
- Dec 2024Grant (prize money)—
#2
Series A · Ottawa, Ontario · founded 2018 · 29 employees$11.6Mraised▾
Developer of viral sensitizer technology therapeutics to treat viral infections. The novel Viral Sensitizer technology consists of a library of small molecules (novel Viral Sensitizers) identified using a high-throughput screening process to target viral infections.
- Apr 2024Series A$60K
- Jan 2024Series A$3M
- Apr 2023Grant (prize money)$790K
- May 2022Series A$5M
#3
Public · Ottawa, Ontario · founded 2015 · 33 employees$37.9Mraised▾
Developer of natural medicinal plant-based elements for treating multiple diseases. It engaged in the development of biopharmaceuticals and natural health products containing Cannabis and other medicinal plant-based elements. Its drug pipeline includes PPP001, a smokable bio-cannabis pharmaceutical for chronic pain, PPP002 to treat Insomnia, and PTSD in chronic pain patients, and PPP003 for chronic pain, PTSD, and other neurologic and psychiatric conditions. The company also develops natural health products for skin care, pain management, etc.
- Mar 2023Grant (prize money)—
- Aug 2022Post IPO—
- May 2022Post IPO$7.5M
- Jan 2021Post IPO$1.9M
#4
Series A · Ottawa, Ontario · founded 2012 · 2 employees$250Kraised▾
NeuroQore develops a monophasic repetitive transcranial magnetic stimulation (rTMS) system for treatment-resistant depression. It includes a semiconductor switch that emits a novel magnetic pulse. The device is undergoing clinical trials for Major Depressive Disorder as of February 2017. The device has received approval in Canada.
- Jul 2025Series A$1.5M
- Oct 2016Seed$250K
#5
Series A · Ottawa, Ontario · founded 2008 · 90 employees$20.9Mraised▾
AI enabled literature review automation software for life sciences researchers. The platform offers DistillerSR and DistillSR modules for automating every stage of the literature review process and search referencing. It also offering AI-enabled screening and quality check options. Users can understand how DistillerSR can automate every step of the literature reviews by accessing a variety of resources on the platform, like case studies, whitepapers, webinars, blogs, and more.
- Aug 2022Series A$20M
- Nov 2020Seed$900K
#6
Series A · Ottawa, Ontario · founded 2017 · 19 employees$16.1Mraised▾
Developer of plant-based biomaterials for repair and regeneration of tissues. The company has developed an open-source platform that uses plant-derived cellulose to create scaffold architectures of organs. The company's products include CelluBridge a proprietary plant-based biomaterial that promotes the repair and regeneration of the spinal cord and CelluJuve a plant-based dermal filler that can assist with everything from injury recovery to cosmetic enhancement.
- Jul 2022Series A$13.2M
- May 2020Seed$2.5M
- Jun 2019Angel$376.8K
#7
Seed · Ottawa, Ontario · founded 2022 · 8 employees$8Mraised▾
Developer of subzero unfrozen cell preservation platform for cell and gene therapy. The company’s platform uses media, temperature, and pressure to preserve biological material. The media formulation leverages cold shock inhibitors and membrane protectants. Temperature systems include devices and shipping solutions. Pressure systems lower the freezing point and cell metabolism, enabling long-term storage.
- Jul 2023Seed$8M
#8
Acqui-Hired · Ottawa, Ontario · founded 2001 · 53865 employees$40.5Mraised▾
Epocal researches and develops biochips and solid-state diagnostic devices. Epocal is implementing an entire blood diagnostic system in FlexCard technology, a card format similar to the smart card used in conventional check and telephone cards. Epocal manufactures cards at ultra low cost, leveraging already existing high volume / low cost production technologies for smart cards. The proprietary FlexCard technology, comprising biosensors and integral fluidics on flex circuit modules in a credit card-sized housing. The company's new enterprise point-of-care blood diagnostic system, the Epoc comprising diagnostic test cards and wireless card readers — is intended to be used in all low volume, distributed testing applications, where high sensitivity and lab quality accuracy is required: in hospitals at the bedside, in physicians' offices and in patients' homes.
- Apr 2007Series C$31M
- Jan 2006Venture Debt$2.5M
- Apr 2005Grant (prize money)$810.6K
- Apr 2005Series B$5.4M
#9
Acqui-Hired · Ottawa, Ontario · founded 2007$6Mraised▾
Atreus Pharmaceuticals was focussed on developing in-vivo radiopharmaceutical products for Nuclear Medicine (SPECT) imaging and for PET imaging. Its product line was based on the Annexin V human protein, which binds to phosphatidylserine, a molecule that only shows up on the surface of dead or dying cells. Its lead diagnostic product Annexin V-128 was in phase 1/2 trials for rheumatoid arthritis and ankylosing spondylitis. It also claims that the compound when used with the medical isotope Technetium-99, has the ability to be used to evaluate the response to treatment for lymphoma and lung cancer. In January 2015, Advanced Accelerator Applications (AAA) fully acquired Atreus.
- Mar 2010Series A$6M
#10
Early Stage · Ottawa, Ontario · founded 2012 · 2 employees$600Kraised▾
GaitTronics has developed a robot which helps seniors in assisted moving. The robot named SoloWalk has completed the product development phase and the launch is targeted for early 2016. The product is targeted towards elders with hip replacement surgery. Owing to the minimal assistance needed, it greatly reduces the effort needed to be provided by care givers.
- Jun 2012Grant (prize money)—
#11
Funding Raised · Ottawa, Ontario · founded 2015 · 6 employees$438Kraised▾
iBIONICS is a Canadian-Australia startup incorporated in Canada to develop implantable bionic devices. They are developing, iBIONICS Diamond Eye, an implant that restores vision enabling the blind to regain autonomy, recognize faces and read large print. It uses diamond electrodes to stimulate the retina, sending messages to the brain perceived as light. It is intended for people afflicted with Age Related Macular Degeneration or Retinitis Pigmentosa leading to blindness.
- Aug 2018Grant (prize money)$438K
#12
Series A · Ottawa, Ontario · founded 2005 · 54 employees$284Kraised▾
Spartan Bioscience manufactures and distributes DNA testing systems. It offers Spartan RX CYP2C19, a DNA testing system and Spartan DX-12, a DNA analyzer for polymerase chain reaction (PCR) applications. The company’s products provide DNA collection, extraction, and analysis services.
- Mar 2015Series A—
- Mar 2013Seed$24K
- May 2012Seed$110K
- May 2009Seed$150K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Ottawa researches in biotechnology
- University of Ottawa16
- Ottawa Hospital8
- Ottawa Research and Development Centre4
- Ottawa Hospital Research Institute4
- Ottawa Fertility Centre1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.